Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 4, 2004, Pages 335-342

  Han, Bo ^a,b   Zhou, Gengyin ^a   Zhang, Qinghui ^a   Zhang, Jing ^c   Wang, Xiaojuan ^a,b   Tang, Weihua ^a,b   Kakudo, Kennichi ^b  

^a SHANDONG UNIVERSITY   (China)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Bcl 2; Lung carcinoma; Pgp

Indexed keywords

ARSENIC TRIOXIDE; GLYCOPROTEIN P; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RELAPSE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFORMATION PROCESSING; INHIBITION KINETICS; LUNG CARCINOMA; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, PHASE-CONTRAST; OXIDES; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 13244268334     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ferlay, J, Bray, F, Pisani, P, Parkin, DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, IARCPress 2001.
2. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL):I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-53, 1997.
3. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
4. Tanaka Y, Komatsu H, Ishii K, Nakamura F, Hayashi T, Sawada H, Ono Y, Imanaka T. Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3) Rinsho Ketsueki. Apr;41(4):354-7, 2000.
5. Murgo, A. J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative research and development studies. Oncologist, 6 (Suppl. 2): 22-28, 2001.
6. Huang C, Ma WY, Li J, Dong Z. Arsenic induced apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59: 3053-3058, 1999.
7. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96: 1525-1530, 2000.
8. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291: 861-7, 2002.
9. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N, Yagi K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-69, 2002.
10. Akao Y, Nakagawa Y, Akiyama K. Arsenic induces apoptosis in neuroblas-toma cell lines in vitro. FEBS Lett 455: 59-62, 1999.
11. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-40, 2001.
12. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma characterizing its apoptotic pathway. Anticancer Drugs 13: 293-300, 2002.
13. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MCG-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-63, 1999.
14. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, Zheng MH. Arsenic trioxide induces apoptosis of esophageal carcinoma in vitro. Int J Mol Med 4: 33-7, 1999.
15. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. J Med Invest. 50(3-4): 126-35, 2003.
16. Volm M. Multidrug resistance and its reversal. Anticancer Res. 18(4C): 2905-17, 1998.
17. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug resistant human myeloid leukemia cells that overexpress MDR_MRP_bcl-2 of bcl-x1. Blood 95(3): 1014-1027, 2000.
18. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. Sep;62(3):529-38, 2002.
19. Wang X, Kong L, Zhao J, Yang P. Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer. Zhonghua Zhong Liu Za Zhi. Jul;24(4):339-43, 2002.
20. Li HC, Wang CX, Huang C, Wang LF, Mu XY, Jiang SJ, Lei ML. Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells Zhonghua Jie He He Hu Xi Za Zhi. 26(11):689-92, 2003.
21. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1;48(3):589-601, 1988.
22. Wu BQ. Establishment of highly metastatic human tumor cell line in nude mice. Zhonghua Zhong Liu Za Zhi. Sep;7(5):324-8, 1985.
23. 3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. Leuk. Lymphoma, 38: 153-163, 2000.
24. Akao, Y., Mizoguchi, H., Kojima, S., Naoe, T., Ohishi, N., and Yagi, K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br. J. Haematol. 102: 1055-1060, 1998.
25. Kroemer G and de The H. Arsenic trioxide, a novel mitochondriotoxic anti-cancer agent? J Natl Cncer Inst 91:743-745, 1999.
26. Zhu XH, Shen YL, Jing Y, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun Y, Dai J, Wang ZY, and Chen SJ. Apoptosis and groth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 91(9): 772-8, 1999.
27. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 101(10):4078-87, 2003.
28. Bosch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y, Leneel T, More MT, Roussakis C. Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res. 17(6D):4595-8, 1999.
29. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X, Ma L. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl). 116(11):1644-8, 2003.
30. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma. 43(6):1221-8, 2002.